Skip to main content

Articles

Page 5 of 21

  1. Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD).

    Authors: Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten and Sebastiaan Engelborghs

    Citation: Alzheimer's Research & Therapy 2020 12:58

    Content type: Research

    Published on:

  2. The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and incre...

    Authors: Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…

    Citation: Alzheimer's Research & Therapy 2020 12:56

    Content type: Review

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2020 12:71

  3. Models of Alzheimer’s disease (AD) pathophysiology posit that amyloidosis [A] precedes and accelerates tau pathology [T] that leads to neurodegeneration [N]. Besides this A-T-N sequence, other biomarker sequen...

    Authors: Meng-Shan Tan, Xi Ji, Jie-Qiong Li, Wei Xu, Hui-Fu Wang, Chen-Chen Tan, Qiang Dong, Chuan-Tao Zuo, Lan Tan, John Suckling and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2020 12:55

    Content type: Research

    Published on:

  4. The contributions of brain intercellular communication mechanisms, specifically extracellular vesicles (EV), to the progression of Alzheimer’s disease (AD) remain poorly understood.

    Authors: Xavier Gallart-Palau, Xue Guo, Aida Serra and Siu Kwan Sze

    Citation: Alzheimer's Research & Therapy 2020 12:54

    Content type: Research

    Published on:

  5. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Claudio Liguori, Fabio Placidi, Francesca Izzi, Matteo Spanetta, Nicola Biagio Mercuri and Alessandra Di Pucchio

    Citation: Alzheimer's Research & Therapy 2020 12:53

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2020 12:5

  6. Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea.

    Authors: Yeong Chan Lee, Jae Myeong Kang, Hyewon Lee, Kiwon Kim, Soyeon Kim, Tae Yang Yu, Eun-Mi Lee, Clara Tammy Kim, Doh Kwan Kim, Matthew Lewis, Hong-Hee Won, Frank Jessen and Woojae Myung

    Citation: Alzheimer's Research & Therapy 2020 12:52

    Content type: Research

    Published on:

  7. The heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subt...

    Authors: Alejandra Machado, Daniel Ferreira, Michel J. Grothe, Helga Eyjolfsdottir, Per M. Almqvist, Lena Cavallin, Göran Lind, Bengt Linderoth, Åke Seiger, Stefan Teipel, Lars U. Wahlberg, Lars-Olof Wahlund, Eric Westman and Maria Eriksdotter

    Citation: Alzheimer's Research & Therapy 2020 12:51

    Content type: Research

    Published on:

  8. Early-onset Alzheimer’s disease (EOAD) is characterized by young age of onset (< 65 years), severe neurodegeneration, and rapid disease progression, thus differing significantly from typical late-onset Alzheim...

    Authors: Giacomo Tondo, Leonardo Iaccarino, Silvia Paola Caminiti, Luca Presotto, Roberto Santangelo, Sandro Iannaccone, Giuseppe Magnani and Daniela Perani

    Citation: Alzheimer's Research & Therapy 2020 12:50

    Content type: Research

    Published on:

  9. There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigati...

    Authors: Peter N. E. Young, Mar Estarellas, Emma Coomans, Meera Srikrishna, Helen Beaumont, Anne Maass, Ashwin V. Venkataraman, Rikki Lissaman, Daniel Jiménez, Matthew J. Betts, Eimear McGlinchey, David Berron, Antoinette O’Connor, Nick C. Fox, Joana B. Pereira, William Jagust…

    Citation: Alzheimer's Research & Therapy 2020 12:49

    Content type: Review

    Published on:

  10. Neuronal hyperexcitability and hypersynchrony have been described as key features of neurophysiological dysfunctions in the Alzheimer’s disease (AD) continuum. Conversely, physical activity (PA) has been assoc...

    Authors: Jaisalmer de Frutos-Lucas, Pablo Cuesta, David López-Sanz, África Peral-Suárez, Esther Cuadrado-Soto, Federico Ramírez-Toraño, Belinda M. Brown, Juan M. Serrano, Simon M. Laws, Inmaculada C. Rodríguez-Rojo, Juan Verdejo-Román, Ricardo Bruña, Maria L. Delgado-Losada, Ana Barabash, Ana M. López-Sobaler, Ramón López-Higes…

    Citation: Alzheimer's Research & Therapy 2020 12:48

    Content type: Research

    Published on:

  11. Amyloid beta (Aβ) which is recognized as a main feature of Alzheimer’s disease (AD) has been proposed to “spread” through anatomically and functionally connected brain regions. The entorhinal cortex and perfor...

    Authors: Rong Jiang, Xue-Fei Wu, Bin Wang, Rong-Xiao Guan, Lang-Man Lv, Ai-Ping Li, Lei Lei, Ye Ma, Na Li, Qi-Fa Li, Quan-Hong Ma, Jie Zhao and Shao Li

    Citation: Alzheimer's Research & Therapy 2020 12:47

    Content type: Research

    Published on:

  12. Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), is characterised by marked deficits within the cholinergic system which are more severe than in ...

    Authors: Julia Schumacher, Alan J. Thomas, Luis R. Peraza, Michael Firbank, Ruth Cromarty, Calum A. Hamilton, Paul C. Donaghy, John T. O’Brien and John-Paul Taylor

    Citation: Alzheimer's Research & Therapy 2020 12:46

    Content type: Research

    Published on:

  13. Chronic neuroinflammation, aggressive amyloid beta (Aβ) deposition, neuronal cell loss, and cognitive impairment are pathological presentations of Alzheimer’s disease (AD). Therefore, resolution of neuroinflam...

    Authors: Min Sung Gee, Seung Hwan Son, Seung Ho Jeon, Jimin Do, Namkwon Kim, Yeon-Joo Ju, Soo Jin Lee, Eun Kyoung Chung, Kyung-Soo Inn, Nam-Jung Kim and Jong Kil Lee

    Citation: Alzheimer's Research & Therapy 2020 12:45

    Content type: Research

    Published on:

  14. Dementia with Lewy bodies (DLB) is more prevalent in men than in women. In addition, post-mortem studies found sex differences in underlying pathology. It remains unclear whether these differences are also pre...

    Authors: M. van de Beek, R. Babapour Mofrad, I. van Steenoven, H. Vanderstichele, P. Scheltens, C. E. Teunissen, A. W. Lemstra and W. M. van der Flier

    Citation: Alzheimer's Research & Therapy 2020 12:44

    Content type: Research

    Published on:

  15. Genome-wide association studies (GWAS) have successfully identified multiple independent genetic loci that harbour variants associated with Alzheimer’s disease, but the exact causal genes and biological pathwa...

    Authors: Zachary F. Gerring, Michelle K. Lupton, Daniel Edey, Eric R. Gamazon and Eske M. Derks

    Citation: Alzheimer's Research & Therapy 2020 12:43

    Content type: Research

    Published on:

  16. Brain amyloid deposition and neurofibrillary tangles in Alzheimer’s disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolis...

    Authors: Matthieu Lilamand, Baptiste Porte, Emmanuel Cognat, Jacques Hugon, François Mouton-Liger and Claire Paquet

    Citation: Alzheimer's Research & Therapy 2020 12:42

    Content type: Review

    Published on:

  18. Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the clo...

    Authors: Carmen Hierro-Bujalance, Carmen Infante-Garcia, Angel del Marco, Marta Herrera, Maria Jose Carranza-Naval, Javier Suarez, Pilar Alves-Martinez, Simon Lubian-Lopez and Monica Garcia-Alloza

    Citation: Alzheimer's Research & Therapy 2020 12:40

    Content type: Research

    Published on:

  19. The Montreal Cognitive Assessment (MoCA) has good sensitivity for mild cognitive impairment, but specificity is low when the original cut-off (25/26) is used. We aim to revise the cut-off on the German MoCA fo...

    Authors: Alessandra E. Thomann, Manfred Berres, Nicolai Goettel, Luzius A. Steiner and Andreas U. Monsch

    Citation: Alzheimer's Research & Therapy 2020 12:39

    Content type: Research

    Published on:

  20. Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.

    Authors: Danielle Newby, Daniel Prieto-Alhambra, Talita Duarte-Salles, David Ansell, Lars Pedersen, Johan van der Lei, Mees Mosseveld, Peter Rijnbeek, Glen James, Myriam Alexander, Peter Egger, Jana Podhorna, Robert Stewart, Gayan Perera, Paul Avillach, Solène Grosdidier…

    Citation: Alzheimer's Research & Therapy 2020 12:38

    Content type: Research

    Published on:

  21. Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer’s disease (AD...

    Authors: Marta Marquié, Sergi Valero, Miguel Castilla-Marti, Joan Martínez, Octavio Rodríguez-Gómez, Ángela Sanabria, Juan Pablo Tartari, Gemma C. Monté-Rubio, Oscar Sotolongo-Grau, Montserrat Alegret, Alba Pérez-Cordón, Natalia Roberto, Itziar de Rojas, Sonia Moreno-Grau, Laura Montrreal, Isabel Hernández…

    Citation: Alzheimer's Research & Therapy 2020 12:37

    Content type: Research

    Published on:

  22. β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...

    Authors: James D. Doecke, Larry Ward, Samantha C. Burnham, Victor L. Villemagne, Qiao-Xin Li, Steven Collins, Christopher J. Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R. Rainey-Smith, Ralph N. Martins and Colin L. Masters

    Citation: Alzheimer's Research & Therapy 2020 12:36

    Content type: Research

    Published on:

  24. TDP-43 type C is one of the pathological forms of frontotemporal lobar degeneration (FTLD) and mainly associated clinically with the semantic variant of primary progressive aphasia (svPPA). We aimed to define ...

    Authors: Martina Bocchetta, Maria del Mar Iglesias Espinosa, Tammaryn Lashley, Jason D. Warren and Jonathan D. Rohrer

    Citation: Alzheimer's Research & Therapy 2020 12:34

    Content type: Research

    Published on:

  25. Pathological analysis of brain tissue from animals and humans with a history of traumatic brain injury (TBI) suggests that TBI could be one of the risk factors facilitating onset of dementia with possible Alzh...

    Authors: Mingfei Li, Joel Reisman, Benjamin Morris-Eppolito, Shirley X. Qian, Lewis E. Kazis, Benjamin Wolozin, Lee E. Goldstein and Weiming Xia

    Citation: Alzheimer's Research & Therapy 2020 12:33

    Content type: Research

    Published on:

  26. After the publication of this article [1], we became aware that there were errors in Figs. 4 and 31.

    Authors: Krystal Sotolongo, Jorge Ghiso and Agueda Rostagno

    Citation: Alzheimer's Research & Therapy 2020 12:32

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2020 12:13

  27. Abnormal beta-amyloid (Aβ) is associated with deleterious changes in central cholinergic tone in the very early stages of Alzheimer’s disease (AD), which may be unmasked by a cholinergic antagonist (J Prev Alz...

    Authors: Jessica Alber, Paul Maruff, Cláudia Y. Santos, Brian R. Ott, Stephen P. Salloway, Don C. Yoo, Richard B. Noto, Louisa I. Thompson, Danielle Goldfarb, Edmund Arthur, Alex Song and Peter J. Snyder

    Citation: Alzheimer's Research & Therapy 2020 12:31

    Content type: Research

    Published on:

  28. As research in treatments for neurocognitive diseases progresses, there is an increasing need to identify cognitive decline in the earliest stages of disease for initiation of treatment in addition to determin...

    Authors: Emma Borland, Erik Stomrud, Danielle van Westen, Oskar Hansson and Sebastian Palmqvist

    Citation: Alzheimer's Research & Therapy 2020 12:30

    Content type: Research

    Published on:

  29. The pathological hallmarks of Alzheimer’s disease (AD) involve alterations in the expression of numerous genes associated with transcriptional levels, which are determined by chromatin accessibility. Here, the...

    Authors: Yaqi Wang, Xiaomin Zhang, Qiao Song, Yuli Hou, Jing Liu, Yu Sun and Peichang Wang

    Citation: Alzheimer's Research & Therapy 2020 12:29

    Content type: Research

    Published on:

  30. Potential moderators such as exercise intensity or apolipoprotein-E4 (ApoE4) carriership may determine the magnitude of exercise effects on physical and cognitive functions in patients with dementia (PwD). We ...

    Authors: L. M. J. Sanders, T. Hortobágyi, E. G. A. Karssemeijer, E. A. Van der Zee, E. J. A. Scherder and M. J. G. van Heuvelen

    Citation: Alzheimer's Research & Therapy 2020 12:28

    Content type: Research

    Published on:

  31. Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD), but diagnosis of AD in DS is challenging due to the intellectual disability which accompanies DS. When disease-modifying agents ...

    Authors: David Mengel, Wen Liu, Robert J. Glynn, Dennis J. Selkoe, Andre Strydom, Florence Lai, H. Diana Rosas, Amy Torres, Vasiliki Patsiogiannis, Brian Skotko and Dominic M. Walsh

    Citation: Alzheimer's Research & Therapy 2020 12:27

    Content type: Research

    Published on:

  32. Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate betwe...

    Authors: Nicolas R. Barthélemy, Randall J. Bateman, Christophe Hirtz, Philippe Marin, François Becher, Chihiro Sato, Audrey Gabelle and Sylvain Lehmann

    Citation: Alzheimer's Research & Therapy 2020 12:26

    Content type: Research

    Published on:

  33. Computerized neuropsychological tests for early detection of Alzheimer’s disease (AD) have attracted increasing interest. Memory for faces and proper names is a complex task because its association is arbitrar...

    Authors: Montserrat Alegret, Nathalia Muñoz, Natalia Roberto, Dorene M. Rentz, Sergi Valero, Silvia Gil, Marta Marquié, Isabel Hernández, Catalina Riveros, Angela Sanabria, Alba Perez-Cordon, Ana Espinosa, Gemma Ortega, Ana Mauleón, Carla Abdelnour, Maitee Rosende-Roca…

    Citation: Alzheimer's Research & Therapy 2020 12:25

    Content type: Research

    Published on:

  34. The functional autonomy assessment is essential to manage patients with a neurodegenerative disease, but its evaluation is not always possible during a consultation. To optimize ambulatory autonomy assessment,...

    Authors: Virginie Dauphinot, Nawèle Boublay, Claire Moutet, Sarah Achi, Anthony Bathsavanis and Pierre Krolak-Salmon

    Citation: Alzheimer's Research & Therapy 2020 12:24

    Content type: Research

    Published on:

  36. The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer...

    Authors: Sanka Amadoru, Vincent Doré, Catriona A. McLean, Fairlie Hinton, Claire E. Shepherd, Glenda M. Halliday, Cristian E. Leyton, Paul A. Yates, John R. Hodges, Colin L. Masters, Victor L. Villemagne and Christopher C. Rowe

    Citation: Alzheimer's Research & Therapy 2020 12:22

    Content type: Research

    Published on:

  37. Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical d...

    Authors: Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo and Susan M. Catalano

    Citation: Alzheimer's Research & Therapy 2020 12:21

    Content type: Review

    Published on:

  38. Until relatively recently, a diagnosis of probable Alzheimer’s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold s...

    Authors: Pawel Obrocki, Ayesha Khatun, Deborah Ness, Konstantin Senkevich, Jörg Hanrieder, Federica Capraro, Niklas Mattsson, Ulf Andreasson, Erik Portelius, Nicholas J. Ashton, Kaj Blennow, Michael Schöll, Ross W. Paterson, Jonathan M. Schott and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2020 12:20

    Content type: Review

    Published on:

  39. The human APOE gene, which codes for apolipoprotein E (apoE), has three major polymorphic alleles: ε2, ε3, and ε4 that give rise to amino acid substitutions. APOE-ε4 is a strong risk factor of sporadic Alzheimer’...

    Authors: K. Minta, G. Brinkmalm, S. Janelidze, S. Sjödin, E. Portelius, E. Stomrud, H. Zetterberg, K. Blennow, O. Hansson and U. Andreasson

    Citation: Alzheimer's Research & Therapy 2020 12:19

    Content type: Research

    Published on:

  40. Biomarkers are increasingly employed for effective research into neurodegenerative diseases. They have become essential for reaching an accurate clinical diagnosis, monitoring disease, and refining entry crite...

    Authors: Ayesha Khatun, Ross W. Paterson and Michael Schöll

    Citation: Alzheimer's Research & Therapy 2020 12:18

    Content type: Review

    Published on:

  42. Crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody, binds to both monomeric and aggregated forms of Aβ. We assessed the pharmacokinetics (PK)/pharmacodynamics (PD...

    Authors: Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin and Angelica Quartino

    Citation: Alzheimer's Research & Therapy 2020 12:16

    Content type: Research

    Published on:

  43. Metabotropic glutamate subtype 5 receptors (mGluR5) modulate synaptic transmission and may constitute an important therapeutic target in Alzheimer’s disease (AD) by mediating the synaptotoxic action of amyloid...

    Authors: Adam P. Mecca, Julia W. McDonald, Hannah R. Michalak, Tyler A. Godek, Joanna E. Harris, Erika A. Pugh, Emily C. Kemp, Ming-Kai Chen, Arash Salardini, Nabeel B. Nabulsi, Keunpoong Lim, Yiyun Huang, Richard E. Carson, Stephen M. Strittmatter and Christopher H. van Dyck

    Citation: Alzheimer's Research & Therapy 2020 12:15

    Content type: Research

    Published on:

  44. Although structural and functional changes of the striatum and hippocampus are present in familial Alzheimer’s disease, little is known about the effects of specific gene mutation or disease progression on the...

    Authors: Meina Quan, Tan Zhao, Yi Tang, Ping Luo, Wei Wang, Qi Qin, Tingting Li, Qigeng Wang, Jiliang Fang and Jianping Jia

    Citation: Alzheimer's Research & Therapy 2020 12:14

    Content type: Research

    Published on:

  45. Mounting evidence points to a crucial role of amyloid-β (Aβ) in the pathophysiology of Alzheimer’s disease (AD), a disorder in which brain glucose hypometabolism, downregulation of central elements of phosphor...

    Authors: Krystal Sotolongo, Jorge Ghiso and Agueda Rostagno

    Citation: Alzheimer's Research & Therapy 2020 12:13

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2020 12:32

  46. Pyroglutamate-3 Aβ (pGlu-3 Aβ) is an N-terminally truncated and post-translationally modified Aβ species found in Alzheimer’s disease (AD) brain. Its increased peptide aggregation propensity and toxicity make ...

    Authors: Helen Crehan, Bin Liu, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Kevin X. Le, Barbara J. Caldarone, Jeffrey L. Frost, Thore Hettmann, Birgit Hutter-Paier, Brian O’Nuallain, Mi-Ae Park, Marcelo F. DiCarli, Inge Lues, Stephan Schilling and Cynthia A. Lemere

    Citation: Alzheimer's Research & Therapy 2020 12:12

    Content type: Research

    Published on:

  47. Evidence from previous studies suggests that bilingualism contributes to cognitive reserve because bilinguals manifest the first symptoms of Alzheimer’s disease (AD) up to 5 years later than monolinguals. Othe...

    Authors: Víctor Costumero, Lidon Marin-Marin, Marco Calabria, Vicente Belloch, Joaquín Escudero, Miguel Baquero, Mireia Hernandez, Juan Ruiz de Miras, Albert Costa, Maria-Antònia Parcet and César Ávila

    Citation: Alzheimer's Research & Therapy 2020 12:11

    Content type: Research

    Published on:

  48. To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we inv...

    Authors: Jolien F. Leijenaar, Geert Jan Groeneveld, Erica S. Klaassen, Anna E. Leeuwis, Philip Scheltens, Henry C. Weinstein, Joop M. A. van Gerven, Frederik Barkhof, Wiesje M. van der Flier and Niels D. Prins

    Citation: Alzheimer's Research & Therapy 2020 12:10

    Content type: Research

    Published on:

  49. Mounting evidence links poor sleep quality with a higher risk of late-life dementia. However, the structural and cognitive correlates of insomnia are still not well understood. The study aims were to character...

    Authors: Oriol Grau-Rivera, Grégory Operto, Carles Falcón, Gonzalo Sánchez-Benavides, Raffaele Cacciaglia, Anna Brugulat-Serrat, Nina Gramunt, Gemma Salvadó, Marc Suárez-Calvet, Carolina Minguillon, Álex Iranzo, Juan Domingo Gispert and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2020 12:4

    Content type: Research

    Published on:

  50. Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology...

    Authors: Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D. Prins…

    Citation: Alzheimer's Research & Therapy 2020 12:8

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193

\